Краткосрочное применение тиклопидина и клопидогреля у больных острым коронарным синдромом без стойких подъемов сегмента St на ЭКГ: влияние на показатели системы гемостаза
Диссертация
Таким образом, обнаруженные в литературе указания на способность тиклопидина быстро усиливать фибринолиз в нашем исследовании, на уровне изменений активности ИТАП, не подтверждаются: кривые средних значений в группе тиклопидина и группе контроля в первые 3-е суток обследования накладываются одна на другую (рис.26). Возможно, профибринолитическое действие тиклопидина, описанное в вышеупомянутой… Читать ещё >
Содержание
- Список сокращений
- Актуальность
- Обоснование краткосрочного применения тиенопиридинов
- Обоснование выбора «фонового» антитромбина
- Цель исследования
- Задачи исследования
- Научная новизна
- Практическая значимость
- Глава 1. Обзор литературы
- Тромбоз — основа развития острых коронарных синдромов
- Антитромбоцитарные ая терапия при ОКСБТБТ
- Роль внутривенных блокаторов ГП ПЬ/Ша рецепторов
- Аспирин
- Тиенопиридины
- Острый коронарный синдром без стойких подъемов сегмента 8 Т на ЭКГ и длительность антитромбоцитарного лечения
- Острый коронарный синдром и система свертывания крови
- Некоторые составляющие систем свертывания крови и фибринолиза, их изменение при ОКС и прогностическое значение. Влияние тиенопиридинов на показатели гемостаза
- Факторы, характеризующие уровень образования и степень активности тромбина
- Фактор фон Виллебранда
- Фибриноген
- Показатели, характеризующие состояние системы фибринолиза
- Глава 2. Материалы и методы
- Материалы
- Методы
- Глава 3. Изменения агрегации тромбоцитов в исследовании с тиклопидином
- Результаты
- Обсуждение
- Глава 4. Изменения агрегации тромбоцитов в исследовании с клопидогрелем
- Результаты
- Обсуждение
- Глава 5. Изменения показателей системы свертывания крови и фактора фон
- Виллебранда
- Изменения показателей системы свертывания крови и фактора фон Виллебранда при применении тиклопидина
- Изменения показателей системы свертывания крови и фактора фон Виллебранда при применении клопидогреля
- Обсуждение
- Глава 6. Изменения показателей системы фибринолиза
- Изменения показателей системы фибринолиза при применении тиклопидина
- Изменения показателей системы фибринолиза при применении клопидогреля
- Обсуждение
- Глава 7. Клинические события
- Клинические события в исследовании с тиклопидином
- Таблица 13. Клинические события в исследовании с тиклопидином
- Клинические события в исследовании с клопидогрелем
- Таблица 16. Клинические события в исследовании с клопидогрелем
- Обсуждение
- Глава 8. Изменения гематологических показателей
- Изменения гематологических показателей в исследовании с тиклопидином
- Таблица 17. Изменения гематологических показателей в исследовании с тиклопидином
- Изменения гематологических показателей в исследовании с клопидогрелем
- Таблица 19. Изменения гематологических показателей в исследовании с клопидогрелем
- Обсуждение
Список литературы
- Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart Journal 2000- 21:1406−1432.
- Cannon CP, Thompson B, McCabe CH, et al: Predictors of non-Q-wave acute myocardial infarction in patients with acute ischemic syndromes: An analysis from the Thrombolysis in Myocardial Ischemia (TIMI) III Trials. Am J Cardiol 1995- 75:977−981.
- Calvin JE, Klein LW, VandenBerg BJ, et al: Risk stratification in unstable angina: Prospective validation of the Braunwald classification. JAMA 1995- 273:136−144.
- Аверков О.В., Затейщиков Д. А., Грацианский Н. А. и др. Нестабильная стенокардия: аспирин и гепарин в двойном слепом плацебо контролируемом исследовании, влияние на исходы в период госпитализации. Кардиология 1993- 5:4−9.
- Аверков О.В., Лысов А. Ю., Эрлих А. Д., Грацианский Н. А. Возможности применения современных рекомендаций по лечению острых коронарных синдромов в инфарктном отделении городской больницы. Кардиология 2002- 4:413.
- Davies MJ, Thomas A. Plaque fissuring the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985- 53:363−373.
- Lewis HD, Davies JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans' Cooperative study. N Engl J Med 1983- 309:396-^03.
- Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988- 319:1105−1111.
- The RISC group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990- 336:827−830.
- Oler A, Whooley MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996−276:811−815.
- Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Circulation 1994- 89:81−88.
- FRISC Study Group. Low molecular weight heparin (Fragmin) during instability in coronary artery disease (FRISC). Lancet 1996- 347:561−568.
- Cohen M, Demers C, Gurfincel EP, et al. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997- 337:447−452.
- Balsano F, Rizzon P, Violi F, et al. Antiplatelet Treatment With Ticlopidine in Unstable Angina: A Controlled Multicenter Clinical Trial. Circullacion 1990- 82:17−26.
- The Clopidogrel in Unstable Angina to Prevent Recurrent Events trial investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001- 345:494−502.
- The Platelet Receptor Inhibition for Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998- 338:1498−1505.
- Ruggeri Z. Receptor-specific antiplatelet therapy. Circulation 1989- 80:1920−1922.
- Fitzgerald DJ, Roy L, Catella F, et al. Platelet activation in unstable coronary disease. N Engl J Med 1986−315:983−989.
- Fuster V, Badimon L, Cohen M, et al. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988- 77:1213−1220.
- Braunwald E, Jones RH, Mark DB, et al. Diagnosis and managing unstable angina. Circulation 1994- 90:613−622.
- Fox KAA Management of high risk unstable angina and non-ST-segment elevation myocardial infarction: variation in practice. Finding from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2000- 21: Abstr. suppl:246.
- White C, Chaitman B, Lassar T, et al. Antiplatelet agents are effective in reducing the immediate complications of PTCA: Results of the ticlopidine multicenter trial (abstract). Circulation 1987- 76(Suppl 4):400.
- Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens following coronary artery stenting. N Engl J Med 1998- 339:1665−1671.
- The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein llb/llla receptor in high-risk coronary angioplasty. N Engl J Med 1994- 330:956−961.
- The EPILOG Investigators: Platelet glycoprotein llb/llla receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997- 336:1689−1696.
- The TARGET investigators. Comparison of two platelet glycoprotein llb/llla inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001- 344: 1888−1894.
- Paganelli F, Alessi MC, Gelisse R, et al. Loading dose of ticlopidine: a simplified approach to intracoronary stent management. Eur Heart J 1999- 20: suppl:532 (abstr).
- Thompson SG, Kienast J, Pyke S, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995- 332:635−41.
- Verheggen P, de Maat M, Cats VM, et al. The predictive value of Fibrinogen, C-reactive protein and lnterleukin-6 on admission in severe unstable angina. J Am Coll Cardiol 1997- abstr. suppl. 791−3.
- Becker RC, Cannon CP, Tracy RP, et al. Fibrinogen, an acute phase protein is not a marker of Thrombin- or Platelet-mediated prothrombotic potential in unstable angina. J Am Coll Cardiol 1997- abstr. suppl 1033−42.
- Нечаев Д.Д., Бочко И. И., Мартынов И.В и др. Преимущества и недостатки антиагрегантов при лечении инфаркта миокарда. Тер. Архив 1988- 60:59−63.
- Love В, Biller J, Gent M. Adverse haematological effects of ticlopidine: prevention, recognition and management. Drug Safety 1998- 19:89−98.
- Bhatt DL, Bertrand ME, Berger PB, et al. Meta-Analysis of randomized and registry comparisons of ticlopidine with Clopidogrel after stenting. Am J Cardiol 2002- 39:9−14.
- Antmann E., Cohen M., Radley D. et al. Assessment of Treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI1 IB-ESSENCE meta-analysis. Circulation 1999- 100:1602−1608.
- Vetrovec GW, Leinbach RC, Gold HK et al. Intracoronary thrombolysis in syndromes of unstable ischemia: angiographic and clinical results. Am Heart J 1982- 104:946−52.
- Mandelkorn JB, Wolf NM, Singh S, Et al. Intracoronary thrombus in nontransmural myocardial infarction and in unstable angina pectoris. Am J Cardiol 1983- 52:1−6.
- Sherman CT, Litvack F, Grundfest W, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986- 315:913−9.
- Uchida Y, Fujimori Y, Hirose J, et al. Percutaneous coronary angioscopy. Jpn Heart J 1992- 33:271−294.
- Mizuno K, Satumo K, Miyamoto A, et al. Angioscopic evaluation of coronary artery thrombi in acute coronarysyndromes. N Engl J Med 1992- 326: 287−291.
- Ambrose JA, Winters SL, Arora RR, et al. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol 1986- 7:472−478.
- Fuster V, Badimon L, Cohen M, et al. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988- 77:1213−1220.
- Willerson JT, Golino P, Eidt J, et al. Platelet mediators and unstable coronary artery disease. Circulation 1989- 80:198−205.
- Theroux P, Latour JG, Leger-Gautier C, et al. Fibrinopeptide A and platelet factor four levels in unstable angina. Circulation 1987−75:156−162.
- Alexopoloulos D, Ambrose JA, Stump D, et al. Thrombosis-related markers in unstable angina. J Am Coll Cardiol 1991- 17:866−871.
- Becker RC, Tracy RP, Bovill EG, et al. for the TIMI-III Thrombosis and Anticoagulation Study Group. The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes. Coronary Art Dis 1994- 5:339−345.
- George JN. Platelets. Lancet 2000- 355:1531−1539.
- Bautista AP, Buckler PW, Towler HM, et al. Measurement of platelet live span in normal subjects and patients with myeloproliferative disease with indium oxine labelled-platelets. Br J Haematol 1984- 58:679−687.
- Avraham H. Regulation of megakaryocytopoiesis. Stem Cells 1993- 11:499−500.
- Vizcaino-Salazar G. Platelet physiology. Advances in platelet reactivity. Rev Invest Clin 1994−35:41−62.
- McEver RP. The clinical significance of platelet membrane glycoproteins. Hematol Oncol Clin North Am 1990- 4:87−105.
- Fukami MH, Salganicoff L. Human platelet storage organelles. A review. Thromb Haemost 1977- 38:963−70.
- Seiss W. Molecular mechanisms of platelet activation. Physiol Rev 1989- 69:58−178.
- Nurden AT, Bihour C, Macchi L, et al. Platelet activation in thrombotic disorders. Nouv Rev Fr Hematol 1993- 35: 67−71.
- Kawai Y, Handa M, Nagai H, et al. Role of membrane glycoproteins in the interaction of blood platelets wiyh the vessel wall the study on platelet adhesion to in vitro cultured subendothelial matrix. Nippon Ketsueki Gakkai Zasshi 1989- 52:13 121 321.
- Weiss HJ, Hawiger J, Ruggeri ZM, et al. Fibrinogen-independent platelet adhesion and thrombus formation on subendotelium mediated by glycoprotein llb/llla complex at high shear rate. J Clin Invest 1989- 83:288−297.
- White JG. Shape change. Thromb Diath Haemorrh 1974- 60:159−171.
- Holmsen H, Day HJ, Stormorken H. The blood platelet release reaction. Scand J Haematol Suppl 1969- 8:1−26.
- Holt JC, Niewiarowski S. Biochemistry of a-granule proteins. Semin Hematol 1985- 22:151−163.
- Kaplan KL, Broekman MJ, Cherhoff A, et al. Platelet alpha granule proteins: studies on release and subcellular localization. Blood 1979- 53:604−618.
- Smith WL, Marnett LJ, De Witt DL. Prostaglandin and thromboxane biosynthesis. Pharmacol Ther 1991- 49:153−179.
- Kinlough-Rathbone RL, Mystard JF, Packham MA, et al. Properties of washed human platelets. Thromb Haemost 1977- 37:291−308.
- Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998- 91:2645−2657.
- Philip G. de Groot. The role of von Willebrand factor in platelet function. Semin Thromb Haemost 2002−28:133−138.
- DeWood M, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980- 303:897−902.
- The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002- 23:1809−1840.
- Willard J, Lange R, Hillis L. The use of aspirin in ischemic heart disease. N Engl J Med 1992- 327:175−181.
- Patrono C. Aspirin as an Antiplatelet Drug. N Engl J Med 1994- 330:1287−1294.
- Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of Canadian Multicenter trial. N Engl J Med 1985- 313:1369−1375.
- Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002- 324:71−86.
- Schror K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997- 23:349−356.
- Stampfer MJ, Jakubowski JA, Deykin D, et al. Effect of alternate-day and enteric-coated aspirin on platelet aggregation, bleeding time, and thromboxane A2 levels in bleeding-time blood. Am J Med 1986- 81:400−404.
- Weiss HJ, Aledort LM, Lochwa S. The effect of salicylates on the hemostatic properties of platelets. J Clin Invest 1968- 47:2169−2180.
- Connor AM, Laposata M. A rapid assay for plaelet thromboxane production and its use in assessing prior aspirin ingestion. Am J Clin Pathol 1988- 89:216−221.
- Meyers KM, Holmsen H, Seachord CL. Comparative study of platelet dense granule constituents. Am J Physiol 1982- 243: R454-R461.
- Gardner A, Jonsen J, Laland S, et al. Adenosine diphosphate in red blood cells as a factor in the adhesiveness of human blood platelets. Nature 1961- 192:531−532.
- Abbracchio MP, Burnstock G. Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmacol Ther 1994- 64:445−475.
- Jin J, Daniel J, Kunapuli S. Molecular basis for ADP-induced platelet aggregation: the P2Y1 receptor mediates ADP-induced intracellular calcium mobilizacion and shape change in platelets. J Biol Chem 1998- 273:2030−2034.
- Sun B, Li J, Okahara K, et al. P2X1 purinoceptor in human platelets: molecular cloning and functional characterization after heterologous expression. J Biol Chem 1998- 273:11 574−11 547.
- Savi P, Bornia J, Savel V, et al. Characterization of P2X1 purinoceptors on rat platelets: effect of clopidogrel. Br J Haematol 1997- 98:880−886.
- Hechler B, Leon C, Vial C, et al. The P2Y1 receptor in necessary for adenosine 5'-diphosphate-induced platelet aggregation. Blood 1998- 92:152−159.
- Leon C, Hechler B, Vial C, et al. The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett 1997- 403:26−30.
- Savi P, Laplase MC, Herbert JM, et al. Evidence for the existence of two different ADP-binding sites on rat platelets. Thromb Res 1994- 76:157−169.
- Savi P, Beauverger P, Labouret C, et al. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett 1998- 422:291−295.
- Daniel J, Dangelmaier C, Jin J, et al. Molecular basis for ADP-induced platelet activation: evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998- 273:2024−2029.
- Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998- 95:80 708 074.
- Defreyn G, Gachet C, Savi P, et al. Ticlopidine and Clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits. Throb Haemost 1991- 65:186−190.
- Gachet C, Savi P, Ohlmann P, et al. ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes: an effect selectively blocked by the thienopyridines Clopidogrel. Thromb Haemost 1992- 68:79−83.
- Savi P, Pflieger AM, Herbert JM. cAMP is not an important messenger for ADP-induced platelet aggregation. Blood Coagul Fibrinolysis 1996- 7:249−252.
- Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of Clopidogrel is due to a metabolic activation by the hepatic cytochrome P450−1A. Thromb Haemost 1994- 72:313−317.
- Di Minno G, Cerbone AM, Mattioli PL, et al. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 1985- 75:328 338.
- Quinn MJ, Fitzgerald DJ. Ticlopidine and Clopidogrel. Circulation 1999- 100:16 671 672.
- Shah J, Fratis A, Ellis D, et al. Effect of food and antacid on absorption of orallyadministered ticlopidine hydrochloride. J Clin Pharmacol 1990- 30:733−736.
- Desager JP. Clinical pharmacokinetics of ticlopidine. Clin Pharmakinet 1994- 26:347−355.
- Herbert JM, Frehel D, Vellee E, et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993- 11:180−198.
- Heptinstall S, May JA, Glenn JR, et al. Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood. Thromb Haemost 1995- 74:1310−1315.
- Chighard M, Lalau Keraly C, Delautier D, et al. Reduced sensitivity of human platelets to PAF-acether following ticlopidine intake. Haemostasis 1989- 19:213−218.
- Cattaneo M, Akkawat B, Lecchi A, et al. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate. Thromb Haemost 1991- 66:694−699.
- Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989- 1:1215−1220.
- Paganelli F, Alessi MC, Gelisse R, et al. Loading dose of ticlopidine: a simplified approach to intracoronary stent management. Eur Heart J 1999- 20: suppl:532 (abstr).
- Darius H, Rupprecht H-J, Kreb P, at al. Accelerated inhibition of platelet activity by Clopidogrel loading dose in patients following coronary stent implantation. Eur Heart J 1999- 20: Abstr. suppl:252.
- Savcic M, Hauert J, Bachmann F, at al. Clopidogrel Loading Dose Regimens: Kinetic Profile of Pharmacodynamic Response in Healthy Subjects. Semin Thromb Hemost 1999−25: Suppl 2:15−19.
- Thebault J-J, Kieffer G, Cariou R. Single Dose Pharmacodynamics of Clopidogrel. Semin Thromb Hemost 1999- 25: Suppl 2:3−8.
- Lau WC, Bates ER, Carville DGM at al. Rapid Platelet Function Assessment Using Two Concentrations of Adenosine Diphosphate After Clopidogrel Loading Dose in Patients Undergoing Cardiac Catheterization. J Am Coll Cardiol 2000−35:1. Abstr. :suppl:43A.
- Panak E, Blanchard J, Roe RL. Evaluation of the antithrombotic efficacy of ticlopidine in man. Agents Actions Suppl 1984- 15: 148−166.
- Coukell AJ, Markham A. Clopidogrel. Drugs 1997- 54:745−750.
- McTavish D, Faulds D, Goa KL, et al. Ticlopidine: an updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990- 40:238−259.
- Gill S, Majumdar S, Brown NE, et al. Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative. Can J Cardiol 1997- 13:909−913.
- Love B, Biller J, Gent M. Adverse haematological effects of ticlopidine: prevention, recognition and management. Drug Safety 1998- 19:89−98.
- Bennett C, Weinberg P, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998- 128:541−544.
- Kupfer Y, Tessler S. Ticlopidine and thrombotic thrombocytopenic purpura. N Engl J Med 1997- 337:1245. Letter.
- Page Y, Tardy B, Zeni F, et al. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 1991- 337:774−776.
- Yim HB, Lieu PK, Choo PW. Ticlopidine induced cholestatic jaundice. Singapore Med J 1997- 38:132−133.
- Hass WK., Easton JD., Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989- 321:501−507.
- The CAPRIE Steering Committee. A randomized, blinded trial of Clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 1996- 348:1329−1339.
- Henry P, Ztot S, deDieuleveut B, et al. Eight days treatment with ticlopidine plus aspirin after successful coronary stenting. Eur Heart J 1998- 19 (Abst suppl): 46.
- Urban P, Gershuck AH, Rupprecht H-J, et al. Efficacy of ticlopidine and Clopidogrel on the rate of cardiac events after stent implantation (abstract). Circulation 1999- 100:1379.
- Moussa I, Oetgen M, Roubin G, et al. Effectiveness of Clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999- 99:2364−2366.
- Muller C, Buttner HJ, Petersen J, et al. A randomized comparison of Clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. Circulation 2000- 101:590−593.
- Mishkel GJ, Aguirre FV, Ligon RW, et al. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. J Am Coll Cardiol 1999- 34:1884−1890.
- Berger PB, Bell MR, Rihal CS, et al: Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 1999- 34:1891−1894.
- Mehta S, Yusuf S, Peters R, et al. Effects of pretreatment with Clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001- 358:527−533.
- Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 2002- 288:2411−2420.
- Balsano F, Coccheri S, Libretti A, et al. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J Lab Clin Med 1989- 114:84−91.
- Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication- effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990- 227:301−308.
- Castelli P, Basellini A, Agus GB, et al. Thrombosis prevention with ticlopidine after femoropopliteal thromboendarterectomy. Int Surg 1986- 71:252−255.
- Yusuf S, Mehta SR, Zhao F, et al. on Behalf of the CURE (Clopidogrel in Unstable angina to prevent Recurrent Events) Trial Investigators. Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes. Circulation 2003- 107:966 972.
- Всероссийское научное общество кардиологов. Лечение острого коронарного синдрома без стойких подъемов сегмента ST на ЭКГ. Российские рекомендации. Кардиология 2001- № 10 (приложение: 1−23).
- Antman Е, McCabe С, Gurfinkel Е, et al. Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non-Q-Wave Myocardial Infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11 В Trial. Circulation 1999- 100:15 931 601.
- FRISC II Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomized multicentre study. Lancet 1999−354:701−707.
- Hawiger L. Adgesive interactions of blood cells and the vascular wall in hemostasis and thrombosis. In «Hemostasis and Trombosis. Basic principles & Clinical practice. (Colman RW, Hirsch J, Mader VJ, et al.) 2001- 639−660.
- Flier JS, Underhill LH. Molecular and cellular biology of blood coagulation. N Engl J Med 1992- 326:800−806.
- Bouchard BA, Butenas S, Mann KJ, et al. Interactions between platelets and the coagulation system. In „Platelets“ (Michelson AD.) 2002- 229−253.
- Dichek D, Quertemous T. Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminoden activator inhibitor-1 in cultured human umbilical vein endothelial cells. Blood 1989- 74:222−228.
- Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992- 89:6998−7002.
- Ольбинская Л.И., Гофман A.M. Лечение и профилактика тромбозов 2000- 1617.
- Панченко Е.П., Добровольский А. Б. Тромбозы в кардиологии. Механизмы развития и возможности терапии. Москва, „Спорт и культура“, 1999.
- Kottke-Marchant К, Bahit М, С, Grander СВ, et al. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes. The GUSTO lib haemostasis substudy. Eur Heart Journal 2002−23:1202−1212.
- Linder R, Oldgren J, Egberg N, et al. The effect of low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease. Eur Heart J Med 1999- 20:506−518.
- Gregorini L., Marco J., Fajadet J., et al. Ticlopidine and Aspirin pretreatment reduces coagulation and platelet activation during coronary dilatation procedures. J Am Coll Cardiol, 1997- 29:13−20
- Lane DA, Bayston TA: Molecular basis of antithrombin action and deficiency. In Schafer Al (ed): Molecular Mechanisms of Hypercoagulable States. Austin, Landes Bioscience, 1997, pp 49−77.
- Scharfstein J.S., Abendschein D.R., Eisenberg P.R., et al. Usefulness of fibrinolytic and procoagulant markers during thrombolytic therapy in predicting cliniccal outcomes in acute myocardial infarction. Am J Cardiol 1996- 78:503−10.
- Gurfincel E., Bazovich G., Pombo G., et al. Acute thrombotic reactant markers in patients with non Q wave coronary events treated with either enoxaparin or unfractionated heparin. Thromb Haemost 1997- (suppl) 286.
- Toss H, Wallentin L, Seigbahn A. Signs of increased fibrinolysis during low molecular weight heparin treatment in unstable coronary artery disease. Eur Heart J 1997- Abstr Suppl:540.
- Mannuccio PM. Von Willebrand factor. A marker of endothelial damage? Arterioscler Thromb Vase Biol 1998- 18:1359−1362.
- Ruggeri Z.M. von Willebrand factor as a target for antithrombotic intervention. Circulation. 1992- 86 9suppl. Ill) III-26-III-29
- Kroll M.H., Harris T.S., Moake J.L., Handin R.I., Schafer A.I. von Willebrand factor binding to platelet Gplb initiates signals for platelet activation. J. Clin. Invest. 1991- 88: 1568−1573
- Cucuianu MP, Missits I, Olinic N, et al. Increased ristocetin-cofactor in acute myocardial infarction: a component of the acute phase reaction. Thromb Haemost 1980- 43:41−44.
- Andreotti F, Roncaglioni C, Hackett DR, et al. Early coronary reperfusion blunts the procoagulant response of plasminogen activtor inhibitor-1 and von Willebrand factor in acute myocardial infarction. J Am Coll Cardiol 1990- 16:1553−1560.
- Folsom AR, Wu KK, Rosamond WD, et al. Prospective study of hemostatic factors and incidence of coronary artery disease: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997- 96:1102−1108.
- Montalescot G, Philippe F, Ankri A, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease. Beneficial effects of enoxaparin. Circulation 1998- 98:294−299.
- Pernerstorfer T, Eichler H-G, Stohlawetz P, et al. Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand factor levels in healthy men. Atherosclerosis 2001- 155:389−393.
- Yarnell JW, Sweetnam PM, Rumley A, et al. Lifestyle and hemostatic risk factors for ischemic heart disease: the Caephilly Study. Arterioscler Thromb Vase Biol 2000- 20:271−279.
- Gokcen M, Yunis E. Fibrinogen as part of platelet structure. Nature 1963- 200:590.
- LopaciukS, Lovette KM, McDonagh J, etal. Subcellular distribution of fibrinogen and factor VIII in human blood platelets. Thromb Res 1976- 8:453−465.
- Davey MG, Luscher EF. Release reactions of human platelets induced by thrombin and other agents. Biochim Biophys Acta 1968- 165:490−506.
- Carlson LA, Bottiger LE, Ahlfeld PE. Risk factors for myocardial infarction in Stocholm Prospective Study. Acta Med Scand 1979- 206:351.
- Meade TW, Mellow S, Brozovic M, et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986- 2:533−537.
- Аверков О.В., Затейщиков Д. А., Грацианский Н. А., Добровольский Н. А. Нестабильная стенокардия: ингибитор тканевого активатора плазминогена идругие факторы гемостаза при приеме аспирина и внутривенном введении гепарина. Кардиология 1993- 8:16−22.
- Al-Nozha М, Gader АМА, Al-Momen АК, et al. Haemostatic Variables in patients with unstable angina. Intern J Cardiol 1994- 43:269−277.
- Giansante C, Calabrese S, Fisicaro M, et al. Treatment of intermittent claudication with antiplatelet agents. J Int Med Res 1990- 18(5):400−407.
- Kirstein P, Jogestrand T, Johnsson H, et al. Antiaggregatory, physiological and clinical effects of ticlopidine in subjects with peripheral atherosclerosis. Atherosclerosis 1980- 36(4):471−480.
- Kroft LJ, de Maat MP, Brommer EJ. The effect of ticlopidine upon plasma fibrinogen levels in patients undergoing suprapubic prostatectomy. Thromb Res 1993- 70(4):349−354.
- Ciuffetti G, Aisa G, Mercuri M, et al. Effects of ticlopidine on the neurologic outcome and the hemorheologic pattern in the postacute phase of ischemic stroke: a pilot study. Angiology 1990- 41(7):505−511.
- DeMaat MP. Effects of diet, drugs, and genes on plasma fibrinogen levels. Ann N Y Acad Sci 2001- 936:509−521.
- DeMaat MP, Arnold AE, van Buuren S, et al. Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris. Thromb Haemost 1997- 77(3):603−604.
- Finelli C, Palareti G, Poggi M, et al. Ticlopidine lowers plasma fibrinogen in patients with polycythaemia rubra vera and additional thrombotic risk factors. A doubleblind controlled study. Acta Haematol 1991- 85(3): 113−118.
- Балуда В.П., Балуда М. В., Деянов И. И. и др. Физиология системы гемостаза 1995−124−126.
- Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993- 88:2030−2034.
- Zalewski A, Shi Y, Nardone D, et al. Evidence for Reduced Fibrinolytic Activity in Unstable Angina at rest. Clinical, Biochemical and Angiographic Correlates. Circulation 1991- 83:1685−1691.
- Huber K, Resch I, Rose D, et al. Heparin induced increase of t-PA antigen levels in patients with unstable angina: no evidence for clinical benefit of heparinization during the initial phase of treatment. Thromb Res 1989- 55:779−764.
- Booth NA, Simpson AJ, Ckoll AA, et al. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. British J Haematol 1988- 70:327−333.
- Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987- 69:381−387.
- Sprengers ED, Princen HM, Kooistra T, et al. Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med 1985- 105:751−758.
- Knudsen BS, Harpel PC, Nachman RL. Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J Clin Invest 1987- 80:1082−1089.
- Kruithof EKO, Tran-Trang C, Bachman F. Studies on the plasminogen activator inhibitor release by human platelets. Thromb Haemost 1986- 55 :201−205.
- Sprengers ED, Akkerman JWN, Jansen B.G. Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood. Thromb Haemost 1986- 55 :325−329.
- Smith FB, Lee AJ, Fowkes FGR, et al. Hemostatic factors as predictors of ischaemic heart disase and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vase Biol 1997- 17:3321−3325.
- Aznar J, Estelles A, Tormo G, et al. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 1988- 59: 535−541.
- Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Circulation 1998- 98:2241−2247.
- Hamsten F, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987- 2:3−9.
- Bounameaux H, de Moerloose P, Perrier A, et al. Plasma measurement of D-dimer as diagnostic aid in suspected venous thromboembolism: An overview. Thromb Haemost 1994- 1:71.
- De Moerloose P, Desmarais S, Bounameaux H, et al. Contribution of a new, rapid, and quantitative automated D-dimer ELISA to exclude pulmonary embolism. Thromb Haemost 1996- 11:75.
- Hoffmeister HM, Szabo S, Kastner C. Thrombolytic Therapy in acute myocardial infarction. Comparitson of procoagulant effects of streptokinase and alteplase regimens with focus on the Kallikrein System and Plasmin. Circulation 1998- 98:2527−2533.
- Ridker PM, Hennekens CH, Cerskus A, et al. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994- 90:2236−2240.
- Oldgren J, Linder R, Grip L, et al. Coagulation activity and clinical outcome in unstable coronary artery disease. Arterioscl Thromb Vase Biol 2001- 21:1059−65.
- Born GVR. Quantitative investigation into the aggregation of blood platelets. J Physiol 1962- 67P-68P.
- Габбасов 3.A., Попов Е. Г., Гаврилов И. Ю. и др. Новый высокочувствительный метод анализа агрегации тромбоцитов. Лабораторное дело 1989- 10:15−18.
- Gabbasov Z.A., Popov E.G., Gavrilov I.Yu., et al. Platelet aggregation: the use of optical density fluctuations to study microaggregate formation in platelet suspension. Thromb Res 1989- 54(3):215−223.
- Габбасов 3.A., Попов Е. Г., Гаврилов И. Ю. и др. Новый методический подход к исследованию агрегации тромбоцитов in vitro. Бюл. экспер. биол. 1989- 10:437 439.
- Trip MD et al. Platelet hyper-reactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990- 322:1549−1554.
- Boneo B, Destelle G. Platelet anti-aggregating activity and tolerance of Clopidogrel in atherosclerotic patients. Tromb Haemost 1996- 76:939−943.
- Defreyn G, Bernat A, Delebassee D, et al. Pharmacology of ticlopidine: a review. Semin Thromb Hemost 1989- 15:159−166.
- Hass WK, Easton JD. Ticlopidine, Platelets and Vascular Disease. Springer Verlag New York 1993: 33 -70.
- L’Allier PL, Aronow Н D, Cura FA, at al. Short Term Mortality Lower With Clopidogrel Than Ticlopidine Following Coronary Artery Stenting. J Am Coll Cardiol 2000- 35: Abst: Suppl:66A.
- Kaul S, Shah PK: Low molecular weight heparin in acute coronary syndrome: Evidence for superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol 2000- 35:1699−1712.
- Margulis Т., David M., Maor N., et al. The von Willebrand factor in myocardial infarction and unstable angina: a kinetic study. Thromb Haemost, 1986,55(3):366−368.
- Montalescot G., Ankri A., Vicaut E., Drobinski G., Grosgogeat Y., Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 1995- 92:31−38
- Yazdani S., Simon A., Kovar L., Wang W» Schwartz A., Rabbani L.E. Percutaneous interventions alter hemostatic profile of patients with unstable angina. J .Am.Coll.Cardiol. 1997- 30:1284−1287
- Eriksson E, Wollter IM, Christenson B, et al. Heparin and Fibrinolysis -Comparison of Subcutaneous Administration of Unfractionated and Low Molecular Weight Heparin. Thromb Haemost 1988- 59:284−288.
- Затейщиков Д.А., Аверков O.B., Грацианский H.A., Добровольский H.A., Сторожилова A.H., Игнашенкова Г. В., Панченко Е. П. Нестабильная стенокардия: тканевой активатор плазминогена, ингибитор тканевого активатора плазминогена, 1991- 4:36−38.
- Gryglewski RJ, Korbut R, Swies J, et al. Thrombolytic action of ticlopidine: possible mechanisms. European J Pharmacol 1996- 308:61−67.
- Vaughan DE, Loscalzo J. Platelet disaggregation in plasma a novel effect of tissue plasminogen activator. Thromb Haemost 1987- 58:431 (abstr).
- Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J Med 1991- 12:157−161.
- Pizzulli L, Zibres M, Yang A, et al. Mean platelet volume and platelet count as clinical marker for unstable angina and the extent of coronary artery disease. Eur Heart J 1995- abstr. suppLabstr 2077.
- Pizzulli L, Yang A, Zibres M, et al. Increase in mean platelet volume as parameter for restenosis following successful percutaneous transluminal coronary angioplasty. Circulation 1997- abstr. suppl.:abstr. 928.
- Gabay G, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999- Vol. 340:448−454.